Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab govitecan + pembrolizumab is a combination therapy for advanced or metastatic triple-negative breast cancer (TNBC). **Sacituzumab govitecan** is a Trop-2-directed antibody-drug conjugate (ADC) that binds to Trop-2, a protein highly expressed on cancer cells, and delivers the cytotoxic agent SN-38, leading to cell death. **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor targeting PD-1, enhancing anti-tumor immune responses. This combination is being investigated as a first-line treatment for unresectable, locally advanced or metastatic PD-L1–positive TNBC, and has demonstrated improved progression-free survival compared to pembrolizumab plus chemotherapy. The combo is also under study for early-stage TNBC. Sacituzumab govitecan is developed and manufactured by Gilead Sciences, while pembrolizumab is developed and manufactured by Merck[2][3][4][5].
- Brand names
- KeytrudaTrodelvy
- Other names
- sacituzumab govitecan-hziy + pembrolizumab
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sacituzumab govitecan + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + pembrolizumab.